Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

NCT06703346 is registered in ClinicalTrials.gov with USWM CT, LLC as lead sponsor.

NCT NCT06703346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06703346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Lead sponsor
USWM CT, LLC
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2019
Completion date
July 24, 2026
Enrollment
82 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms